Clinical Trial Update: A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years [Phase 2]

View source ↗

Summary

Phase 2 study assessing immunogenicity, safety, and tolerability of the bivalent recombinant lipoprotein 2086 vaccine against meningococcal infection in childre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Infection

Drugs mentioned

• Bivalent rLP2086 (rLP2086 (N. meningitidis outer membrane protein complex))

Snippet

Sponsor: Pfizer | Conditions: MENINGOCOCCAL INFECTION | Phase 2 | Status: COMPLETED | Results posted: 2018-03-27